Safety and Efficacy of Allogeneic Natural Killer Cells in Combination with Pembrolizumab in Patients with Chemotherapy-Refractory Biliary Tract Cancer: A Multicenter Open-Label Phase 1/2a Trial.
Galam LeemSung-Ill JangJae-Hee ChoJung Hyun JoHee Seung LeeMoon-Jae ChungJeong Youp ParkSeungmin BangDa-Kyung YooHyo-Cheon CheonJae-Eun KimKyeong-Pill LimIn-Hye JungJung-Min ImYong-Yoon ChungSeung Woo ParkPublished in: Cancers (2022)
SMT-NKs plus pembrolizumab resulted in no severe AEs directly related to the drug combination. The combination therapy also exerted antitumor activity with improved efficacy compared to the recent monotherapy with pembrolizumab in patients with advanced biliary tract cancer.
Keyphrases
- combination therapy
- open label
- papillary thyroid
- advanced non small cell lung cancer
- natural killer cells
- phase iii
- squamous cell
- clinical trial
- phase ii
- study protocol
- stem cell transplantation
- emergency department
- bone marrow
- lymph node metastasis
- randomized controlled trial
- low dose
- childhood cancer
- high dose
- locally advanced
- electronic health record